Comparison · NCT00862745-sae
Fesoterodine vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Fesoterodine vs Placebo: serious adverse events. Trial comparisons, record NCT00862745-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00862745-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0124 | 0.00484 | 0.0315 | wilson | |
| Risk in group 2 | 0.0124 | 0.00483 | 0.0314 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0000385 | -0.0204 | 0.0206 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1 | 0.253 | 3.98 | log | |
| Odds ratio, group 1 over group 2 | 1 | 0.249 | 4.05 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Fesoterodine than on Placebo | 26,000 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Fesoterodine | fesoterodine 4 mg (1 tablet) for 2 weeks with the option to increase to fesoterodine 8 mg or stay at fesoterodine 4 mg for 10 weeks for a total of 12 weeks of study medication. | 4 | 322 | EG000 |
| Group 2 | Placebo | placebo (an identical pill that contains no medication) 1 tablet daily for 2 weeks followed by the option to increase the placebo pill daily for 10 weeks for a total of 12 weeks of study placebo medication. | 4 | 323 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Baseline through Week 12 (Randomized Control Trial portion of the study).
Source ClinicalTrials.gov
Trial
- Title
- Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)
- NCT number
- NCT00862745
- Phases
- PHASE4
- Conditions
- Urge Urinary Incontinence, Overactive Bladder
- Interventions
- Fesoterodine, Matching Placebo
- Lead sponsor
- University of California, San Francisco
- Results first posted
- 2011-11-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00862745?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00862745-sae